The Efficacy and Safety of Nemolizumab in Patients with Prurigo Nodularis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Hicham Titou

doi:10.5826/dpc.1504a5967

The Efficacy and Safety of Nemolizumab in Patients with Prurigo Nodularis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Authors

Hicham Titou Department of Dermatology-Venereology, Avicenne Military Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco

Keywords:

prurigo nodularis, biologic, meta-analysis

References

Galderma receives U.S. FDA approval for Nemluvio (nemolizumab) for adult patients living with prurigo nodularis. News release. Galderma. August 13, 2024. Accessed January 1, 2025.

Ständer S, Fofana F, Dias-Barbosa C, et al. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis. Dermatol Ther (Heidelb). 2023;13(7):1587-1602. doi:10.1007/s13555-023-00962-8.

Brooks SG, Yosipovitch G. A critical evaluation of nemolizumab for prurigo nodularis. Expert Rev Clin Immunol. 2024;20(6):577-587. doi:10.1080/1744666X.2024.2306225

Downloads

PDF
PREVIEW

Published

2025-10-31

Issue

Vol. 15 No. 4 (2025): 2025 Vol 15, No 4 | October

Section

Letter to the Editor

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

Titou H. The Efficacy and Safety of Nemolizumab in Patients with Prurigo Nodularis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Dermatol Pract Concept. 2025;15(4):5967. doi:10.5826/dpc.1504a5967